Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literature. (PubMed, Skin Health Dis) - Oct 1, 2026 - "We present a 26-year-old woman diagnosed with PG, initially managed with systemic corticosteroids and ciclosporin...Despite treatment with azathioprine, infliximab and, later, ustekinumab, the patient experienced repeated flares of both PG and CD...This case adds to the growing body of evidence supporting the use of IL-23 inhibitors, particularly guselkumab, in recalcitrant PG associated with systemic inflammatory comorbidities. Guselkumab may offer a promising therapeutic alternative in the management of treatment-resistant PG, especially in patients with coexisting CD."
Journal • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Pain • Pyoderma Gangrenosum • IL23A
|
|
Osmanege Atliya; Tarkan Karakan
|